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Cyclin D1, an important component of cell cycle and a
protein with known oncogenic potential, is over expressed
in mantle cell lymphoma (MCL). MCL is a distinct clinical
pathologic subtype of B cell non-Hodgkin’s lymphoma
often associated with poor prognosis. New therapeutic
approaches based on boosting anti-tumor immunity are
being developed. Targeting cyclin D1 for MCL is render-
ing an interesting target for immunotherapy. However, the
knowledge on the frequency and profile of cyclin D1-spe-
cific T cells in MCL patients is fragmented. Here we show
that both healthy individuals and MCL patients have a
broad repertoire of cyclin D1-specific CD4+ and CD8+
T cells covering numerous epitopes from the whole cyclin
D1 protein. Cyclin D1-specific T cells secrete IFN-g and
type 2 cytokines including IL-5 and IL-13. Additionally,
DCs loaded with whole tumor cells or with selected pep-
tides can elicit cyclin D1-specific CD8+ T cells that kill
MCL tumors. Furthermore, a recombinant vaccine based
on targeting cyclin D1 antigen to human DCs via an anti-
CD40 mAb was developed. Targeting monocyte-derived
human DCs in vitro with anti-CD40-cyclin D1 fusion pro-
tein expanded a broad repertoire of cyclin D1-specific
CD4+ and CD8+ T cells. Therefore, cyclin D1 represents a
good target for immunotherapy.
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